Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 14/20 | 0.49 |
| ▸ | FLT3 | P36888 | 14/20 | 0.49 |
| ▸ | SRC | P12931 | 3/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.43 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | SIK1 | P57059 | 1/20 | 0.42 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.42 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.42 |
| ▸ | CDK7 | P50613 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22917725 | 1.00 | KIT (0.49) | KITFLT3SRCNTRK1CHEK1 | |
| SCHEMBL22917727 | 1.00 | KIT (0.49) | KITFLT3SRCNTRK1CHEK1 | |
| SCHEMBL22917463 | 0.92 | SRC (0.49) | KITFLT3SRCCHEK1LCK | |
| SCHEMBL29616333 | 0.92 | SRC (0.49) | KITFLT3SRCCHEK1LCK | |
| SCHEMBL29616151 | 0.89 | FLT3 (0.54) | KITFLT3SRCNTRK1CHEK1 | |
| SCHEMBL22917505 | 0.85 | FLT3 (0.47) | KITFLT3SRCNTRK1LIMK1 | |
| SCHEMBL28912502 | 0.85 | FLT3 (0.47) | KITFLT3SRCNTRK1LIMK1 | |
| SCHEMBL22917630 | 0.83 | KIT (0.45) | KITFLT3SRCNTRK1CHEK1 | |
| SCHEMBL28912478 | 0.83 | KIT (0.45) | KITFLT3SRCNTRK1CHEK1 | |
| SCHEMBL29911550 | 0.83 | KIT (0.45) | KITFLT3SRCNTRK1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220288069-A1 | INHIBITORS OF TYROSINE KINASE | BRIDGENE BIOSCIENCES, INC. | 2022-09-15 | — | — | US | disclosed |
| EP-3999064-A1 | INHIBITORS OF TYROSINE KINASE | Bridgene Biosciences, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288069-A1 | INHIBITORS OF TYROSINE KINASE | ABL1, SRC, LCK | KIT 688/4885FLT3 41/4885SRC 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.